OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Other research analysts have also issued research reports about the stock. Stephens reiterated an “equal weight” rating and issued a $4.00 price objective on shares of OncoCyte in a research note on Wednesday, April 17th. Benchmark restated a “speculative buy” rating and set a $5.00 price target on shares of OncoCyte in a research note on Monday, April 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $4.25 price target on shares of OncoCyte in a research note on Thursday, May 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.06.

OncoCyte Price Performance

OCX stock opened at $2.95 on Friday. OncoCyte has a 12 month low of $2.08 and a 12 month high of $4.86. The firm has a 50 day simple moving average of $2.73 and a 200 day simple moving average of $2.90.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($1.13) EPS for the quarter. The firm had revenue of $0.18 million during the quarter. OncoCyte had a negative net margin of 2,905.14% and a negative return on equity of 135.45%. As a group, research analysts expect that OncoCyte will post -2.58 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Andrew Arno bought 33,898 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the transaction, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Andrew Arno acquired 33,898 shares of the stock in a transaction on Thursday, April 11th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the transaction, the director now owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the stock in a transaction on Thursday, April 11th. The stock was bought at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the transaction, the insider now directly owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The disclosure for this purchase can be found here. Insiders bought 2,457,288 shares of company stock worth $7,176,400 in the last quarter. 1.94% of the stock is owned by corporate insiders.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.